Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 16/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | DKK1 | O94907 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519390 | 1.00 | IKBKB (0.72) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL4659228 | 1.00 | IKBKB (0.72) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL3520678 | 0.84 | IKBKB (1.00) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL4659200 | 0.84 | IKBKB (0.69) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL4661782 | 0.84 | IKBKB (0.69) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL4659204 | 0.84 | IKBKB (0.69) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL3517290 | 0.82 | IKBKB (0.78) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL3519092 | 0.81 | IKBKB (0.69) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL3518049 | 0.80 | IKBKB (0.79) | IKBKBMAPK8MAPK10DKK1GSK3B | |
| SCHEMBL3519764 | 0.79 | IKBKB (0.97) | IKBKBMAPK8MAPK10DKK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101460491-A | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH CORP (US) | 2009-06-17 | — | — | CN | claimed |
| EP-2004638-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-24 | — | — | EP | claimed |
| WO-2007120593-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | WYETH (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | claimed |
| CN-101460491-A | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH CORP (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | ABCG2, CYP3A43, CYP2D6 | IKBKB 4165/4885MAPK8 4424/4885MAPK10 4473/4885 |
| US-20080262009-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS ACETATE SALTS | CYP2F1, CYP4B1, CYP3A4 | IKBKB 4538/4885MAPK8 4352/4885MAPK10 4350/4885 |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | IKBKB 3482/4885MAPK8 4342/4885MAPK10 3605/4885 |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | IKBKB 4349/4885MAPK8 4180/4885MAPK10 3546/4885 |
| US-20080262008-A1 | useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph | CSNK1A1, PRKX, PRKACA | IKBKB 327/4885MAPK8 127/4885MAPK10 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.